Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc (NYSE: MDT) is a Galway, Ireland-based healthcare technology company whose news flow reflects its broad activity in medical devices, diabetes technology, surgical robotics, and cardiovascular therapies. Company announcements frequently highlight regulatory milestones, clinical evidence, product launches, capital markets activity, and corporate governance developments that matter to investors and healthcare professionals following MDT stock.
Recent news has featured U.S. Food and Drug Administration clearances for key technologies, including the Hugo robotic-assisted surgery (RAS) system for urologic procedures and the MiniMed Go Smart Multiple Daily Injection (MDI) system, which connects the InPen smart insulin pen and the Instinct sensor made by Abbott through the MiniMed Go app. Medtronic has also reported on the broad U.S. commercial launch of the MiniMed 780G automated insulin delivery system integrated with the Instinct sensor, expanding its diabetes technology ecosystem.
Investors can also track Medtronic’s cardiovascular and hypertension-related developments, such as the final National Coverage Determination from the U.S. Centers for Medicare & Medicaid Services for the Symplicity Spyral renal denervation system, and updates on growth drivers like pulsed field ablation and other cardiovascular therapies discussed in earnings releases. Financial news includes quarterly earnings reports, guidance updates, dividend declarations, and details of senior notes offerings and redemptions.
This MDT news page aggregates coverage of topics including diabetes business developments (such as the planned MiniMed IPO registration), conference presentations, leadership and board changes, and major clinical or reimbursement milestones. Readers interested in Medtronic’s role in chronic disease management, minimally invasive surgery, and global healthcare technology can use this page to follow ongoing announcements and review the company’s evolving strategic priorities over time.
Medtronic (NYSE: MDT) received FDA clearance for its Midas Rex™ high-speed drills and navigated interbody tools integrated with the Mazor™ Robotic Guidance System. This early approval enhances the surgical workflow by improving precision and predictability, which is expected to lead to better patient outcomes. The upgraded Mazor platform offers 3D visualization, increased efficiency, and the ability to visualize disc prep during procedures. The company aims to transform spinal care by addressing customer needs with advanced technologies.
Medtronic plc (NYSE: MDT) announced positive outcomes from the OPuS One Clinical Study involving the OsteoCool™ Radiofrequency Ablation (RFA) System. The study, the largest of its kind for bone metastases, demonstrated significant and swift pain relief in the first 100 patients, with improvements noted just three days post-procedure and sustained for up to six months. Key findings include an 87% incidence of thoracolumbar spine tumors among participants and effective pain management for patients inadequately treated by traditional methods. Results were published in the November edition of the Journal of Vascular and Interventional Radiology.
On December 14, 2020, Medtronic plc (NYSE:MDT) announced Sean Salmon's appointment as Executive Vice President and President of the Cardiovascular Portfolio, effective January 1. He will retain his role leading the Diabetes Operating Unit. Salmon succeeds Mike Coyle, who departs to become CEO of another company. Medtronic's Chairman, Geoff Martha, praised Salmon's leadership experience and success in previous roles. Salmon aims to drive growth and innovation in both the Diabetes and Cardiovascular sectors to enhance patient outcomes.
Medtronic plc (NYSE: MDT) announced a cash dividend of $0.58 per share for the third quarter of fiscal year 2021, approved by the board on December 11, 2020. This follows the dividend announcement made in June 2020, and is consistent with Medtronic's history as a member of the S&P 500 Dividend Aristocrats index, having raised its annual dividend for 43 consecutive years. The dividend will be payable on January 15, 2021, to shareholders of record as of December 22, 2020.
Medtronic plc (NYSE:MDT) has launched the Carpediem™ Cardio-Renal Pediatric Dialysis Emergency Machine in the U.S. following FDA marketing authorization. This innovative system, designed specifically for patients weighing 2.5 to 10 kilograms, addresses the critical needs of young patients with acute kidney injury or fluid overload, providing safer and more effective hemodialysis. The first units are now in use at Cincinnati Children's Hospital Medical Center, enhancing the treatment options for neonates, who face a high mortality rate from kidney injuries.
Medtronic plc (NYSE:MDT) announced its participation in the Evercore ISI 3rd Annual HealthCONx Conference, scheduled for December 3, 2020. Mike Weinstein, SVP of Strategy, will address questions starting at 8:50 a.m. EST. A live audio webcast will be accessible via the Investors Events link on Medtronic's investor relations website, with an archived replay available later the same day. Medtronic, headquartered in Dublin, Ireland, is a leading global medical technology company, employing over 90,000 individuals and serving patients in more than 150 countries.
Medtronic plc (NYSE:MDT), a leader in medical technology, will participate virtually in the Piper Sandler 32nd Annual Healthcare Conference on December 2, 2020. Mike Coyle, Executive Vice President and President of the Cardiovascular Portfolio, will address inquiries starting at 10:30 a.m. EST. A live audio webcast of the session will be accessible through the Investors Events link on Medtronic's investor relations website, with an archived playback available later. Medtronic focuses on advancing healthcare worldwide, employing over 90,000 people across more than 150 countries.
Medtronic has announced an additional $3.8 million commitment to support healthcare workers and communities during the COVID-19 pandemic, raising its total relief efforts to more than $46 million. This initiative focuses on emergency food assistance, mental health support, and PPE donations, including over 400,000 masks. The Medtronic Foundation will also provide $1.6 million in grants to nonprofits assisting low-income communities. CEO Noel Colón emphasized the importance of this support for frontline workers and underserved populations.
Medtronic plc (NYSE:MDT) reported its Q2 fiscal year 2021 results, with revenue of $7.6 billion, marking a decrease of 0.8% reported and 1.5% organically. The company's GAAP EPS was $0.36, while non-GAAP EPS was $1.02, both down 22%. U.S. revenues fell 2% while non-U.S. developed market revenue increased 6%. The Cardiac and Vascular Group and Diabetes Group faced declines of 5.5% and 5%, respectively, though the Minimally Invasive Therapies Group saw a 6.2% organic increase. The company refrained from providing future guidance due to ongoing COVID-19 uncertainties.
Medtronic plc (NYSE:MDT) plans to announce its financial results for Q2 FY2021 on November 24, 2020, at 5:45 a.m. CST. The announcement will include key financial metrics for the quarter ending October 30, 2020. A webcast discussing these results will be held at 7:00 a.m. CST on the same day. Medtronic also scheduled to report FY2021 Q3 and Q4 results on February 23, 2021, and May 27, 2021, respectively. Investors are encouraged to visit their website for updates.